NCT01689259View on ClinicalTrials.gov

Comparative Pharmacokinetics and Safety of TNX-102 SL Tablets and Cyclobenzaprine Oral Tablet in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

March 31, 2014

Conditions
Healthy Adults
Interventions
DRUG

SL TNX-102 at 2.4 mg

1 TNX-102 SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing it.

DRUG

SL TNX-102 at 4.8 mg

2 TNX-102 SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing them.

DRUG

SL TNX-102-A at 2.4 mg

1 TNX-102-A SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing it.

DRUG

Cyclobenzaprine tablets

1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water

Trial Locations (1)

G1P 0A2

PharmaNet, Inc., Québec

All Listed Sponsors
lead

Tonix Pharmaceuticals, Inc.

INDUSTRY

NCT01689259 - Comparative Pharmacokinetics and Safety of TNX-102 SL Tablets and Cyclobenzaprine Oral Tablet in Healthy Adults | Biotech Hunter | Biotech Hunter